
Streamline gene therapy development and other AAV-based applications
With a simple one-step protocol to concentrate AAV particles from media, you can streamline your gene therapy development and other projects that rely on AAV transduction.
- Easy to use, single reagent
- Isolate rAAV directly from media
- No cell lysates or centrifugation
- Save time and cost-effective
- Compatible with all serotypes

Figure 1. AAVanced Concentration Reagent delivers AAV particle preps with similar titers as AAV particles prepared using conventional methods. rAAV was packaged with a PGK-GFP expression shuttle vector. The rAAV particles were isolated from packaging cell media either by the conventional method—cell lysis freeze-thaw with density gradient ultracentrifugation—or with the AAVanced Concentration Reagent. Equal amounts of rAAV were then added to HEK293 cells to test for infectivity based on GFP expression. Representative images of GFP expressing cells 10-days after infection show similar levels of infectivity.